--- title: "Modulate excessive VEGF levels in prethreshold ROP eyes. | Sutter Health" description: "Systemic measures can be taken that may reduce the risk of blindness in infants with prethreshold ROP." url: "https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Modulate excessive VEGF levels in prethreshold ROP eyes. # Rethinking STOP-ROP: Is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP. Gaynon MW. _Retina. 26(7 Suppl):S18-23._ 2006-09-01 ## Abstract PURPOSE: To review systemic modifiable factors that might downregulate pathologic levels of vascular endothelial growth factor (VEGF) in prethreshold retinopathy of prematurity (ROP), and thereby reduce the risk of blindness in affected infants. METHODS: Review of the author's clinical experience as compared to the STOP-ROP study, and discussion and literature review of the potential effects of oxygen supplementation, light adaptation state, and correction of severe anemia on the course of prethreshold retinopathy of prematurity (ROP). RESULTS: Moderate oxygen supplementation, combined with light adaptation to reduce retinal oxygen consumption and correction of severe anemia, were associated, in the author's experience, with improvement in the clinical course of prethreshold ROP. Withdrawal of these measures was often associated with deterioration of ROP. CONCLUSION: Systemic measures can be taken that may reduce the risk of blindness in infants with prethreshold ROP. For those infants who require laser treatment for threshold ROP, prior efforts to moderate excessive levels of VEGF may improve the chances of a successful surgical result, by slowing the momentum of the disease. [PubMed abstract](http://www.ncbi.nlm.nih.gov/pubmed/16946672) ## Research topics - [Maternal and Infant Health](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Maternal+and+Infant+Health%5C%22%22) - [Disease Management](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Disease+Management%5C%22%22) - [Neurological Disorders](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Neurological+Disorders%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.](https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290) Kantor AB, Deng J, Waubant E, Lin H, Becker CH, Lacy JR, Perrone AM, Bennett D, Goelz SE. J Neuroimmunol. 188(1-2):103-16. Epub 2007 Jul 5. 2007 Aug 01 - Publication ### [Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation.](https://www.sutterhealth.org/research/publications/chronic-demyelinate-polyneuropathy-lymph-radiation-1055312345) Rosenberg NL, Lacy JR, Kennaugh RC, Holers VM, Neville HE, Kotzin BL. Muscle Nerve. 8(3):223-32. 1985 Mar 01 - Publication ### [Interferon beta-1a in children with multiple sclerosis is well tolerated.](https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304) Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, Miller C, Rensel M, Schwid S, Goodkin D. Neuropediatrics. 32(4):211-3. 2001 Aug 01 - Publication ### [International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2011.](https://www.sutterhealth.org/research/publications/world-report-on-assisted-reproductive-technology-2011-1055312366) Adamson GD, de Mouzon J, Chambers GM, Zegers-Hochschild F, Mansour R, Ishihara O, Banker M, Dyer S. Fertil Steril. 110(6):1067-1080. doi: 10.1016/j.fertnstert.2018.06.039. 2018 Nov 01 - Publication ### [Impact of frozen-thawed single-blastocyst transfer on maternal and neonatal outcome: an analysis of 277,042 single-embryo transfer cycles from 2008 to 2010 in Japan.](https://www.sutterhealth.org/research/publications/one-blastocyst-transfer-matern-infant-outcome-1055312440) Ishihara O, Araki R, Kuwahara A, Itakura A, Saito H, Adamson GD. Fertil Steril. 101(1):128-33. doi: 10.1016/j.fertnstert.2013.09.025. Epub 2013 Oct 23. 2014 Jan 01 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Modulate excessive VEGF levels in prethreshold ROP eyes."}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982#medicalscholarlyarticle","name":"Rethinking STOP-ROP: Is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP.","headline":"Modulate excessive VEGF levels in prethreshold ROP eyes.","abstract":"PURPOSE: To review systemic modifiable factors that might downregulate pathologic levels of vascular endothelial growth factor (VEGF) in prethreshold retinopathy of prematurity (ROP), and thereby reduce the risk of blindness in affected infants. METHODS: Review of the author's clinical experience as compared to the STOP-ROP study, and discussion and literature review of the potential effects of oxygen supplementation, light adaptation state, and correction of severe anemia on the course of prethreshold retinopathy of prematurity (ROP). RESULTS: Moderate oxygen supplementation, combined with light adaptation to reduce retinal oxygen consumption and correction of severe anemia, were associated, in the author's experience, with improvement in the clinical course of prethreshold ROP. Withdrawal of these measures was often associated with deterioration of ROP. CONCLUSION: Systemic measures can be taken that may reduce the risk of blindness in infants with prethreshold ROP. For those infants who require laser treatment for threshold ROP, prior efforts to moderate excessive levels of VEGF may improve the chances of a successful surgical result, by slowing the momentum of the disease.","description":"Systemic measures can be taken that may reduce the risk of blindness in infants with prethreshold ROP.","keywords":["Maternal and Infant Health","Disease Management","Neurological Disorders"],"datePublished":"2006-09-01","url":"https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"16946672"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/16946672/"],"isPartOf":{"@type":"Periodical","name":"Retina"},"author":[{"@type":"Person","name":"Gaynon MW"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Maternal and Infant Health","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Maternal+and+Infant+Health%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Disease Management","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Disease+Management%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Neurological Disorders","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Neurological+Disorders%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982#breadcrumblist"}}} ```